

SUPPLY AGREEMENT WITH MAJOR US HEALTHCARE PROVIDER FOR ROVER PLUS UNITS

Adelaide, Australia, 30 July 2025: Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a leader in cold cathode x-ray technology for health and security markets globally, is pleased to announce it has entered into a Supply Agreement with a major U.S. healthcare services provider for its Rover Plus mobile radiology system (**Customer**). The Customer operates a nationwide network of hospitals, surgical centres, and outpatient facilities, and is one of the largest and most established healthcare organisations in the United States. This Supply Agreement marks a major commercial milestone for Micro-X. It is the Company's first agreement with a major U.S. healthcare provider and follows a successful in-hospital evaluation and competitive tender process conducted in 2024. The Rover Plus is now approved for procurement by the Customer's member hospitals and facilities across the U.S., without the need for further evaluation or internal tender processes.

Key points

- Micro-X enters new Supply Agreement for Rover Plus units with with a top-tier U.S. healthcare group
- Customer operates a broad network of over 700 healthcare facilities, including acute hospitals, surgical centres and outpatient services
- Supply Agreement awarded to Micro-X following an open tender for mobile radiology systems and a successful in hospital evaluation of the Rover Plus
- Micro-X's first agreement for supply of Rover Plus with a major healthcare provider in the US
- Supply Agreement contains standard commercial terms including supply timeframes, warranties and tiered pricing for orders
- Rover Plus added to the Customer's approved procurement list
- Negotiations for second Rover Plus sales opportunity - with a major procurement group - is ongoing

Micro-X Chief Executive Officer, Kingsley Hall commented:

"We are extremely pleased to have secured this initial supply agreement with one of the largest and most respected healthcare groups in the United States, who treat over 8.5 million patients annually. Most significant is that this is Micro-X's first supply agreement with a major US healthcare provider and opens the doors for member hospitals to buy the Rover without the need to run an evaluation or tender for new equipment. The global healthcare market is generally conservative, typically relying on well established brands and hesitant to procure critical medical equipment from new vendors. Micro-X worked for nearly a year to demonstrate the value of Rover and to build trust with the Customer, culminating in this supply agreement. We see this as the key step in the execution of our commercial objective of establishing Micro-X as a medical imaging vendor, starting with Rover Plus and growing into a future of CT."

Micro-X Chief Sales Officer, Scott Bryant commented:

"This outcome highlights the truly differentiating factors of the Rover Plus as a highly versatile and reliable unit which can provide mobile radiology solutions in a range of hospital and healthcare settings. The sales and technical teams have worked tirelessly to drive this outcome, and now that Rover Plus is an approved procurement item, moving forward we will be supporting the Customer to address their needs for new and replacement mobile radiology systems, with our Micro-X Rover Plus. We look forward to our first orders."

Summary of Supply Agreement

- Awarded following a competitive tender and clinical evaluation across four hospitals within the Customer's U.S. network
 - Initial agreement term of three years
 - Covers tiered pricing, supply lead times, and standard commercial terms including warranty, product specifications and compliance obligations
 - Approval on the procurement list opens sales opportunities
 - Micro-X holds \$4.0 million in Rover Plus inventory and is preparing its supply chain to support anticipated demand

Disclosure and ASX Compliance

In accordance with ASX Listing Rules, Micro-X confirms the following:

1. The identity of the Customer has not been disclosed at the request of the Customer. As a major procurer of equipment across a large network of medical facilities, the Customer does not allow their name to be used by suppliers and does not provide any endorsement of equipment they choose to purchase.
2. Micro-X has assessed this request and considers that the Customer's identity is not information that a reasonable person would expect to have a material effect on the price or value of the Company's securities.
3. This announcement contains all material information necessary to assess the impact of the contract on the price or value of the Company's securities and is not misleading by omission.
4. Micro-X further confirms that the Customer has not endorsed or approved the Rover Plus product, and the Supply Agreement does not constitute or imply any form of product endorsement, exclusive arrangement, or formal approval of Micro-X or its technologies.

This ASX Announcement is authorised by the Board of Micro-X.


– ENDS –

About Micro-X

Micro-X Limited is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control emitters with this technology enables x-ray products with significant reduction in size, weight, and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio spans a number of high margin, product applications in health and security. The first mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military and veterinary applications. The US Department of Homeland Security has contracted Micro-X to design a next-generation Airport security checkpoint. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government's Medical Research Future Fund. In November 2024, US Government agency ARPA-H contracted Micro-X to develop a full-body CT.

For more information visit: www.micro-x.com



Contacts

Micro-X Limited	Investor Enquiries
<p>Kingsley Hall, Chief Executive Officer Rebecca Puddy, Head of Corporate Communications Tel: +61 8 7099 3966 Email: media@micro-x.com</p>	<p>David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 Email: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com</p>

